FLORAPHAGE CLINICAL DATA

ENZYME	PUBLICATION	SUBJECTS	INTERVENTION	DURATION	ENDPOINTS	RESULTS
Phage	Bruttin et al 2005	15	n/a	2 days	Safety	Subjects underwent fecal and serum tests to determine safety of phage therapy. No adverse events were reported and other tests were in normal range. This was considered the first step in the rational evaluation of phage therapy in humans.
T-4 Phage Cocktail	Sarker et al 2012	15	3 billion PFU/day	n/a	Safety and oral application	Subjects underwent fecal tests to determine whether oral administration resulted in detectable levels. 64% of samples had detectable phage. No adverse events were reported.
Floraphage	n/a	in vitro	n/a	10 hours	Growth of E. coli	Testing demonstrated that Floraphage decreased the plated growth of the strain E. coli over a period of 10 hours vs growth without Floraphage which increased over the study period. This result lead to further analysis.
Floraphage	n/a	in vitro	n/a	n/a	Popular probiotic plated growth with and without Floraphage	Testing of four popular probiotic products plated with and without Floraphage demonstrated that the study product improved the growth rate of every probiotic product tested. It was also uncovered that Florphage was especially impactful on Bacillus Subtilis growth rates, which were found in the product Syntol.
Phage	Barr et al 2013	in vitro	n/a	n/a	Mucus adherence	In vitro testing demonstrated phage's ability to adhere to intestinal mucosal surfaces, which protects the underlying epithelium from possible infection.
Floraphage	n/a	in vitro	n/a	48 hours	Bifidobacterium growth increase	Testing demonstrated that Floraphage improved the plated growth of the strain B. longum 500x over a period of 48 hours vs growth with the prebiotic Inulin.
Floraphage	n/a	in vitro	n/a	5 hours	Bifidobacterium growth increase	Testing demonstrated that Floraphage improved the plated growth of the strain B. Breve 130x over a period of 5 hours vs growth without Floraphage.